Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Pemetrexed (ALIMTA), a novel multitargeted antineoplastic agent.

Alex A Adjei1

  • 1Mayo Clinic and Foundation, Departments of Oncology, Rochester, Minnesota, USA. adjei.alex@mayo.edu

Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|June 26, 2004
PubMed
Summary

Pemetrexed is an effective chemotherapy drug for various cancers, including lung cancer. Supplementing with folic acid and vitamin B12 reduces its toxicity without affecting its anti-cancer efficacy.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Defining Cardiovascular Endpoints in Oncology Trials: Challenges and Opportunities: A Scientific Statement From the American Heart Association.

Circulation·2026
Same author

Defining Cardiovascular Endpoints in Oncology Trials: Challenges and Opportunities: A Scientific Statement From the American Heart Association.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026
Same author

The Impact of Immunotherapy on Incidence of Second Primary Malignancies: A Surrogate for Antitumor Surveillance Activation.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026
Same author

The Perils of AI-Generated Peer Review.

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer·2026
Same author

20 Years of Breakthroughs: Transforming the Fight Against Thoracic Malignancies.

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer·2026
Same author

Long-term outcomes of Extensive-Stage small cell lung cancer treated with chemotherapy or Chemo-immunotherapy: A propensity score adjusted cohort study.

Lung cancer (Amsterdam, Netherlands)·2025

Area of Science:

  • Oncology
  • Pharmacology
  • Biochemistry

Background:

  • Pemetrexed is a novel antimetabolite targeting key folate pathway enzymes.
  • It exhibits clinical activity across multiple solid tumors, notably non-small cell lung cancer (NSCLC).

Purpose of the Study:

  • To evaluate the efficacy and toxicity of pemetrexed in solid tumors.
  • To assess the impact of folic acid and vitamin B12 supplementation on pemetrexed's side effects.

Main Methods:

  • Clinical trials (Phase II and III) investigated pemetrexed as a single agent and in combination therapies.
  • Dietary supplementation with folic acid and vitamin B12 was administered to assess toxicity modulation.

Main Results:

  • Pemetrexed demonstrated single-agent activity in first- and second-line NSCLC treatment.

Related Experiment Videos

  • Combinations with platinum compounds, vinorelbine, and gemcitabine showed promising results.
  • Folic acid and vitamin B12 supplementation significantly reduced mucosal and bone marrow toxicity.

    • Conclusions:

    • Pemetrexed is a valuable chemotherapeutic agent for NSCLC and other solid tumors.
    • Dietary supplementation effectively mitigates pemetrexed-induced toxicity, enhancing patient tolerability without compromising antitumor effects.